Organised by the European Forum Against Blindness (EFAB). Supported by Novartis, Alcon and Second Sight Medical Products as a service to medicine and patients
Blindness and vision loss are preventable and should become a health priority over the next years. Raising awareness, timely diagnosis and prevention can greatly reduce the burden of eye diseases.
The European Forum Against Blindness (EFAB) is organising this workshop to discuss how eye diseases and preventable blindness have a huge impact on society and can be avoided through timely diagnosis and prevention. Join us for an in-depth overview of the cost of blindness throughout Europe.
The first ever Pan-European data on the direct and indirect costs of preventable blindness will be presented, showcasing unique evidence on how screening, and early diagnosis and treatment of vision loss is possible, and cost effective, and therefore should be a healthcare priority. EFAB will bring together relevant stakeholders of the eye health sector to engage with them in a high-level debate on the importance of addressing preventable blindness in the EU.
Glendon Harris, Board Member, European Forum Against Blindness (EFAB)
Omer Saka, Director, Market Access Strategy and Health Economics Group, Deloitte, Belgium
Herbert Reitsamer, Senior physician, Ophthalmology and Optometry Clinic, University Hospital, Paracelsus Medical University, Austria
Elio Borgonovi, SDA Bocconi University, Italy and President, Research Centre of Health and Social Service Management (CERGAS)
Renate Heinisch, Member of the European Economic and Social Committee (EESC), former MEP and pharmacist
Ian Banks, Chair of European Forum Against Blindness (EFAB) and President of European Men’s Health Forum